Stockscreener 앱 받기
1.28
1.54%
-0.02
전일 마감가:
$1.30
열려 있는:
$1.3
하루 거래량:
254.46K
Relative Volume:
0.09
시가총액:
$14.35M
수익:
-
순이익/손실:
$-11.66M
주가수익비율:
-0.1569
EPS:
-8.156
순현금흐름:
$-11.09M
1주 성능:
-17.42%
1개월 성능:
-39.34%
6개월 성능:
-30.43%
1년 성능:
-42.08%
1일 변동 폭
$1.26
$1.31
1주일 범위
$1.26
$1.64
52주 변동 폭
$0.9657
$9.79
Phio Pharmaceuticals Corp Stock (PHIO) Company Profile
명칭
Phio Pharmaceuticals Corp
전화
(508) 767-3861
주소
411 SWEDELAND ROAD, KING OF PRUSSIA, MA
PHIO을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
PHIO
Phio Pharmaceuticals Corp
|
1.275 | 14.35M | 0 | -11.66M | -11.09M | -8.156 |
|
ARGX
Argen X Se Adr
|
932.01 | 55.90B | 3.06B | 1.28B | 447.35M | 19.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.45 | 110.91B | 11.74B | 3.68B | 3.34B | 14.19 |
|
INSM
Insmed Inc
|
197.06 | 41.21B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
ONC
Beone Medicines Ltd Adr
|
382.54 | 40.48B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
707.82 | 72.89B | 14.25B | 4.58B | 3.88B | 41.77 |
Phio Pharmaceuticals Corp Stock (PHIO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-06-05 | 재개 | H.C. Wainwright | Buy |
| 2020-08-05 | 개시 | H.C. Wainwright | Buy |
Phio Pharmaceuticals Corp 주식(PHIO)의 최신 뉴스
Phio Pharmaceuticals Announces Upcoming Podium Presentation at the Advanced Therapies USA 2025 Congress - MarketScreener
Phio Pharmaceuticals (NASDAQ: PHIO) to Present INTASYL siRNA at Advanced Therapies USA - Stock Titan
How Phio Pharmaceuticals Corp. (44R1) stock reacts to new regulationsJuly 2025 Institutional & Fast Momentum Stock Entry Tips - newser.com
Will Phio Pharmaceuticals Corp. (44R1) stock profit from AI boomWeekly Trade Recap & High Conviction Investment Ideas - newser.com
How Phio Pharmaceuticals Corp. (44R1) stock reacts to fiscal policiesIndex Update & Low Volatility Stock Recommendations - newser.com
Can Phio Pharmaceuticals Corp. hit a new high this monthBond Market & Safe Capital Growth Tips - newser.com
Is Phio Pharmaceuticals Corp. stock attractive for retirement portfoliosWeekly Stock Report & Safe Capital Growth Trade Ideas - newser.com
Is Phio Pharmaceuticals Corp. stock supported by strong fundamentalsPortfolio Risk Summary & Free Growth Oriented Trading Recommendations - newser.com
Is Phio Pharmaceuticals Corp. (44R1) stock included in top ETFsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
Will Phio Pharmaceuticals Corp. stock outperform tech sector in 2025Market Risk Report & Verified Momentum Stock Watchlist - Fundação Cultural do Pará
How Phio Pharmaceuticals Corp. stock performs after earningsJuly 2025 Action & Entry Point Confirmation Alerts - Fundação Cultural do Pará
Phio Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - Newsfile
Can Phio Pharmaceuticals Corp. rally from current levelsJuly 2025 Trade Ideas & Daily Stock Momentum Reports - newser.com
What drives Phio Pharmaceuticals Corp 44R1 stock priceMACD Histogram Signals & Analyze Your Portfolio Risk in Seconds - earlytimes.in
Top chart patterns to watch in Phio Pharmaceuticals Corp.Market Performance Report & Long-Term Capital Growth Ideas - newser.com
Best data tools to analyze Phio Pharmaceuticals Corp. stockEarnings Risk Summary & Risk Controlled Swing Trade Alerts - newser.com
Developing predictive dashboards with Phio Pharmaceuticals Corp. data2025 Technical Overview & Low Volatility Stock Recommendations - newser.com
Using economic indicators to assess Phio Pharmaceuticals Corp. potentialEarnings Summary Report & Accurate Entry/Exit Alerts - newser.com
Analyzing Phio Pharmaceuticals Corp. with multi timeframe charts2025 Price Targets & Weekly High Momentum Picks - newser.com
Its Stock Has Paid Off Big Time For Phio Pharmaceuticals Corp - setenews.com
Phio Pharmaceuticals to Present Recent Clinical Results from Skin Cancer Trial with siRNA based INTASYL PH-762 - Newsfile
Phio’s INTASYL PH-762 wins immunomodulatory solution of the year By Investing.com - Investing.com South Africa
Phio’s INTASYL PH-762 wins immunomodulatory solution of the year - Investing.com
Phio Pharmaceuticals Announces INTASYL PH-762 is Named Immunomodulatory Solution of the Year in the BioTech Breakthrough Award Program - Newsfile
Phio Pharma (NASDAQ: PHIO) to present Phase 1b PH-762 skin cancer results at SITC - Stock Titan
Phio Pharmaceuticals Exercises Warrants for $13.4 Million - TipRanks
Is Phio Pharmaceuticals Corp. stock in correction or buying zoneJuly 2025 Big Picture & AI Enhanced Trading Alerts - newser.com
How Phio Pharmaceuticals Corp. stock benefits from tech adoptionGlobal Markets & Expert Curated Trade Setup Alerts - newser.com
How currency fluctuations impact Phio Pharmaceuticals Corp. stockWeekly Stock Summary & Risk Adjusted Buy and Sell Alerts - newser.com
Phio Pharmaceuticals Corp (PHIO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.58%
1.53%
자본화:
|
볼륨(24시간):